Study summary · research use only
Discovery of a follistatin-derived myostatin inhibitory peptide
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this mouse study, researchers focused on the N-terminal domain of follistatin, which interacts with the myostatin type I receptor binding site, and tested synthetic fragment peptides in an in vitro luciferase reporter assay. The abstract reports identification of DF-3, a 14-mer peptide, as inhibiting myostatin but not activin A or TGF-β1 in this assay. When injected intramuscularly, DF-3 was associated with a significant increase in skeletal muscle mass in mice, which the authors describe as indicating potential for a myostatin-inhibition-based approach to muscle enhancement.
Abstract
Follistatin is well known as an inhibitor of transforming growth factor (TGF)-β superfamily ligands including myostatin and activin A. Myostatin, a negative regulator of muscle growth, is a promising target with which to treat muscle atrophic diseases. Here, we focused on the N-terminal domain (ND) of follistatin (Fst) that interacts with the type I receptor binding site of myostatin. Through bioassay of synthetic ND-derived fragment peptides, we identified DF-3, a new myostatin inhibitory 14-mer peptide which effectively inhibits myostatin, but fails to inhibit activin A or TGF-β1, in an in vitro luciferase reporter assay. Injected intramuscularly, DF-3 significantly increases skeletal muscle mass in mice and consequently, it can serve as a platform for development of muscle enhancement based on myostatin inhibition.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.